These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Protein changes in non-LDL-lipoproteins in familial hypercholesterolemia: implications in cardiovascular disease manifestation and outcome. Badimon L; Padró T; Cubedo J Curr Opin Lipidol; 2017 Oct; 28(5):427-433. PubMed ID: 28682808 [TBL] [Abstract][Full Text] [Related]
26. Detecting Familial hypercholesterolemia in children and adolescents: potential and challenges. Banderali G; Capra ME; Biasucci G; Stracquadaino R; Viggiano C; Pederiva C Ital J Pediatr; 2022 Jul; 48(1):115. PubMed ID: 35840982 [TBL] [Abstract][Full Text] [Related]
27. Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia. Ravnskov U; de Lorgeril M; Kendrick M; Diamond DM Med Hypotheses; 2018 Dec; 121():60-63. PubMed ID: 30396495 [TBL] [Abstract][Full Text] [Related]
29. Serious flaws in targeting LDL-C reduction in the management of cardiovascular disease in familial hypercholesterolemia. Ravnskov U; de Lorgeril M; Kendrick M; Diamond DM Expert Rev Clin Pharmacol; 2021 Mar; 14(3):405-406. PubMed ID: 33565344 [TBL] [Abstract][Full Text] [Related]
30. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E; Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068 [TBL] [Abstract][Full Text] [Related]
31. Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia. Pérez de Isla L; Ray KK; Watts GF; Santos RD; Alonso R; Muñiz-Grijalvo O; Diaz-Diaz JL; Badimon L; Catapano AL; Mata P Atherosclerosis; 2019 Jul; 286():40-45. PubMed ID: 31100618 [TBL] [Abstract][Full Text] [Related]
32. The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. Gallo A; Pérez de Isla L; Charrière S; Vimont A; Alonso R; Muñiz-Grijalvo O; Díaz-Díaz JL; Zambón D; Moulin P; Bruckert E; Mata P; Béliard S; JACC Cardiovasc Imaging; 2021 Dec; 14(12):2414-2424. PubMed ID: 34274263 [TBL] [Abstract][Full Text] [Related]
33. Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. Alonso R; Díaz-Díaz JL; Arrieta F; Fuentes-Jiménez F; de Andrés R; Saenz P; Ariceta G; Vidal-Pardo JI; Almagro F; Argueso R; Prieto-Matos P; Miramontes JP; Pintó X; Rodriguez-Urrego J; Perez de Isla L; Mata P J Clin Lipidol; 2016; 10(4):953-961. PubMed ID: 27578128 [TBL] [Abstract][Full Text] [Related]